Source comparison
Fat Loss Peptides Men Over 40 Dad Bod: Evidence-Based Comparison
Before selecting a peptide protocol, understanding mechanism-specific outcomes matters more than generic 'fat loss' claims. This table compares the three most-researched peptide classes for visceral fat reduction in men over 40. GLP-1 Agonists (semaglutide, ti
This comparison does not assign a generated winner or score.
- Before selecting a peptide protocol, understanding mechanism-specific outcomes matters more than generic 'fat loss' claims. This table compares the three most-researched peptide classes for visceral fat reduction in men over 40.
- GLP-1 Agonists (semaglutide, tirzepatide)
- Appetite suppression via hypothalamic GLP-1 receptor activation + improved insulin sensitivity
- 20–30% visceral fat reduction at 68 weeks (STEP-1 trial)
- Subcutaneous injection, weekly
- 16–24 weeks minimum for meaningful fat loss
- Best first-line option for men over 40 with elevated fasting insulin or prediabetes. Addresses root insulin resistance driving visceral fat accumulation
- GH Secretagogues (CJC-1295/ipamorelin)
- Restored pulsatile GH secretion → increased lipolysis via hormone-sensitive lipase activation
- 12–18% visceral fat reduction at 24 weeks (observational studies)
- Subcutaneous injection, twice daily
- 12–16 weeks minimum for measurable IGF-1 elevation
- Most effective when baseline IGF-1 is below 150 ng/mL. Targets age-related GH decline directly but requires consistent twice-daily dosing
- Oral GH Secretagogues (MK 677)
- Ghrelin receptor agonism → sustained GH elevation + IGF-1 increase
- 8–15% visceral fat reduction at 24 weeks (JCEM 2-year study)
- Oral, once daily
- 8–12 weeks minimum for IGF-1 elevation
- Convenience advantage with once-daily oral dosing. Lower magnitude fat loss than injectable GLP-1 agonists but better lean mass preservation
- Dual GIP/GLP-1 Agonists (tirzepatide)
- Dual incretin receptor activation → appetite suppression + enhanced insulin sensitivity + possible direct lipolytic signaling
- 25–35% visceral fat reduction at 72 weeks (SURMOUNT-1 trial)
- 20–28 weeks for maximal effect
- Highest magnitude fat loss of any single peptide. Combines GLP-1 mechanism with GIP receptor-mediated improvements in adipocyte insulin sensitivity